Vivalis acquires single-cell antibody from SC World

28 April 2011

French drug firm Vivalis (Euronext: VLS) says it has acquired high-throughput screening (HTS) single-cell antibody discovery technology from SC World, a privately-held company based in Toyama, Japan.

The assets transferred by SC World include intellectual property (including various patents co-owned with Toyama Prefecture), know-how and physical assets enabling Vivalis to utilize the HTS single-cell technology for human monoclonal antibody discovery. Concurrent with the agreement with SC World, Vivalis has obtained an exclusive license agreement with the Toyama Prefecture, co-owner of certain single cell technology patents, thereby granting the French group an exclusive world-wide license to these patents.

Financial terms include up front, milestones and earn out based on revenues. Further details were not revealed. Taking into account this investment, Vivalis confirms its cash guidance at the end of 2011 of approximately 30 million euros ($43.7 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK